drugset / Trial / NCT05347498

A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults

NCT05347498

Phase 1 Unknown 90 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy and safety of HR091506 tablets for treatment of primary gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.

Timeline

Start
2022-04-30
Primary completion
2022-07-31
Completion
2022-07-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Febuxostat Small molecule 40 mg
Comparator Febuxostat Small molecule 80 mg
Subject HR091506 Unknown 40 mg
Subject HR091506 Unknown 80 mg

Indications